Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.
Kareem Karara, PharmD, BCPS, CCHP: As far as unbranded biologics that may be targeted for pipeline development in the near future, I’d love to see expanded options in the autoimmune and oncology disease spaces. These are 2 areas that are commonly managed with a range of biologic therapies and biosimilars, and they continue to be areas where we see growth of biologic management in terms of how we manage these diseases.
Regarding the future implications of unbranded biologics and biosimilars, I’m excited to see what’s to come. It’s important to see increased competition in the market for biologic drugs, which ultimately will improve patient access to these clinically important therapies and the role they have in managing chronic disease.
Transcript edited for clarity.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
